Skip to Main Content

Paper Details

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
109
2016
Author NameAffiliation
Alexander A VinksCincinnati Children's Hospital Medical Center
Russel HirschCincinnati Children's Hospital Medical Center
  • 1 - 2

Datasets

Release 1.2